Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-22T23:40:20.587Z Has data issue: false hasContentIssue false
  • English
  • Français

Combined fluoxetine and disulfiram treatment of alcoholism with comorbid affective disorders. A naturalistic outcome study, including quality of life measurements

Published online by Cambridge University Press:  16 April 2020

C Børup  and
M Undén
C Børup
Affiliation:
Psychiatric Dept, Hvidovre Hospital, Copenhagen
M Undén
Affiliation:
Sct Hans Hospital, Dept M, Roskilde, DK-4000, Denmark
Get access

Summary

This uncontrolled study presents 188 patients primarily diagnosed as addictive alcoholics and fulfilling the DSM III diagnostic criteria for panic disorder or major depression, 104 and 84 patients, respectively. The study focused on clinical outcome of pharmacological intervention with combined fluoxetine and disulfiram treatment. The patients were followed for (up to) 40 months. A good clinical outcome for both groups was found in 70%. In a subgroup of 37 patients ‘quality of life’ was assessed using quality of life scales. An appropriate correlation emerged between clinical judgement of outcome and the patients’ self-rating. Although the study was limited by being uncontrolled, the results have shown, that specific treatment in a group of alcoholics with comorbid psychopathology within the anxiety and depression spectrum is possible even after many years of addictive alcohol abuse. The necessity for proper psychiatric assessment is stressed.

Keywords

addictive alcoholismpanic disordermajor depressionfluoxetinedisulfiramclinical outcomequality of life
Type
Original article
Information
European Psychiatry , Volume 9 , Issue 2 , 1994 , pp. 83 - 89
Copyright
Copyright © European Psychiatric Association 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, edn 3. Washington, DC, 1980Google Scholar
Ballenger, JCGoodwin, FKMajor, LFBrown, GL. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatr 1979;36:224-7CrossRefGoogle ScholarPubMed
Bech, P. Quality of life in psychosomatic research. Psychopathol 1987;20:169-79CrossRefGoogle ScholarPubMed
Bech, PTørning, J. Alkoholisme: Psykopatologi og livskvalitet. Månedsskr prakt Lægegerning 1992;9:785-93Google Scholar
Bech, PAllerup, PMaier, WAlbus, MLavori, PAyuso, JL. The Hamilton Scales and the Hopkins Symptom Checklist (SCL-90): a crossnational validity study in patients with panic disorders. Br J Psychiatr 1992;160:206-11CrossRefGoogle Scholar
Bech, P. Rating Scales for Psychopathology, Health Status and Quality of Life.A compendium on documentation in accordance with the DSM III-R and WHO systems. Springer: Berlin, 1993Google Scholar
Bruno, FBuspirone in the treatment of alcoholic patients. Psychopathol 1989;22:(suppl 1):49–59CrossRefGoogle ScholarPubMed
Cowen, PJ. Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatr 1991;59:(suppl 12):7–14CrossRefGoogle Scholar
Dupuy, HJ. The Psychological general well-being (PGWB) index, In: Wenger, NK. Mattson, MEFurburg, CDElinson, J eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing, 1984;184-8Google Scholar
George, DTZerby, ANoble, SNull, DJ. Panic attacks and alcohol withdrawal: can subjects differentiate the symptoms? Biol Psychiatry 1988;2:240-3CrossRefGoogle Scholar
Guy, W. Early Clinical Drug Evaluation (ECDEU) Assessment Manual. Rockville: National Institute of Mental Health, 1976Google Scholar
Hatsukami, DPickens, RW. Posttreatment depression in an alcohol and drug abuse population. Am J Psychiatr 1982; 139:1563-6Google Scholar
Kushner, MGSher, KJBeitman, BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatr 1990;47:685-95Google Scholar
Litten, RZAllen, JP. Pharmacotherapies lor alcoholism: promising agents and clinical issues. Alcohol Clin Exp Res 1991;15:620-33CrossRefGoogle Scholar
Markowitz, JSWeismann, MMQuéllette, RLish, JDKlerman, GL. Quality of life in panic disorder. Arch Gen Psychiatr 1989;46:984-92CrossRefGoogle ScholarPubMed
Meyer, REKranzler, HR. Alcoholism: clinical implications of recent research. J Clin Psychiatr 1988;49:(suppl 9):8–12Google ScholarPubMed
Naranjo, CASellers, EMSulivan, TWoodley, DVKadlec, KSykora, K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987;41:266-74CrossRefGoogle ScholarPubMed
Naranjo, CAKadlec, KESanhueza, PWoodley-Remus, DSellers, EM. Fluoxetine differentially alters alcohol intake and other consumatory behaviour in problem drinkers. Clin Pharmacol Ther 1990;7:490-8CrossRefGoogle Scholar
Tarlov, ARWare, JEGreenfiels, SNelson, CPerrin, EZubkoff, M. The medical outcomes study. An application of methods for monitoring the results of medical care. JAMA 1989;262:925-30CrossRefGoogle ScholarPubMed
Tollefson, GD. Anxiety and alcoholism: a serotonin link. Br J Psychiatry 1991;159:(suppl 12):34-9CrossRefGoogle Scholar
Zerbe, R. Safety of fluoxetine. Br J Clin Pract 1986;40:(suppl 46):41-7Google Scholar
Submit a response

Comments

No Comments have been published for this article.